Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.Karen L. Kotloff, Myron M. Levine|PubMed|1999Cited by 1.3k
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoitesD A Herrington, Myron M. Levine, Genevieve A. Losonsky et al.|Nature|1987Cited by 503
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trialMilagritos D. Tapia, Myron M. Levine|The Lancet Infectious Diseases|2015Cited by 215
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans.Myron M. Levine, M F Edwards, D A Herrington et al.|Journal of Clinical Investigation|1987Cited by 189
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strainsJames P. Nataro, J. Glenn Morris, J Seriwatana et al.|Infection and Immunity|1995Cited by 182